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Three of the papers contained in this supple-
ment cover aspects of a symposium titled ‘The
modern gladiatorial arena: Gram-positive patho-
gens versus new therapies’ which was held at
the 14th European Congress of Clinical Micro-
biology and Infectious Diseases in Prague, Czech
Republic, in May 2004. These papers review the
prevalence of resistant pathogens in Europe, the
effectiveness of currently available therapies,
areas of unmet clinical need, and the way in
which unmet needs might be addressed in the
future. They are preceded by a fourth paper
which provides a review of the mechanisms of
antibiotic resistance in Gram-positive bacteria.
One of the antibiotics that promises to be
relevant to unmet needs is daptomycin, an agent
with a unique mode of bactericidal action. The
antibiotic was discovered by Eli Lilly and Com-
pany (Lilly) in the early 1980s and was under
development as LY146032, for the intravenous
treatment of serious Gram-positive infections.
Despite promising trials for the treatment of skin
and soft tissue infections and endocarditis Lilly
suspended trials in 1991 because of concerns
regarding skeletal muscle toxicity. Later in the
decade, interest in daptomycin returned because
of the increasing prevalence of infections caused
by Gram-positive pathogens that were resistant to
many antibiotics. In 1997, Cubist Pharmaceuticals
received rights to the drug on the premise that
modiﬁed dosing regimens would be clinically
effective without the risk of skeletal muscle
toxicity. Clinical trials (at a dosage of 4 mg/kg
once daily) supported this premise and in Sep-
tember 2003 the drug was approved by the US
Food and Drug Administration for the treatment
of complicated skin and soft tissue infections
caused by susceptible Gram-positive bacteria,
including methicillin-resistant and methicillin-
susceptible Staphylococcus aureus. Chiron Biophar-
maceuticals has in-licensed the commercial rights
to daptomycin in Western and Eastern Europe,
Australia, New Zealand, India and certain Central
American, South American and Middle Eastern
countries. Daptomycin is currently undergoing
further trials to assess its potential to address
unmet needs, particularly in the treatment of
serious skin and soft tissue infections.
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